VICTOR RIVERA to Cohort Studies
This is a "connection" page, showing publications VICTOR RIVERA has written about Cohort Studies.
Connection Strength
0.020
-
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
Score: 0.011
-
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62.
Score: 0.009